BOTHELL, Wash.--(BUSINESS WIRE)--EKOS Corporation, a privately held medical device company located in Bothell, Washington, announced today the completion of their second major trial for the treatment of pulmonary embolism (PE). The SEATTLE II study is a 150 patient single arm prospective study measuring the rapid reduction in right heart strain in a patient population with both massive and submassive PE. Robert W. Hubert, President and CEO of EKOS Corporation, cited U.S. patient statistics: “There are over 600,000 cases of PE each year alone of which upwards of 45% are considered major having significant clot in one or both pulmonary arteries. This clot burden interferes with the heart’s ability to pump blood into the lungs for oxygenation, causing enlargement of the right side of the heart. Not removing the clot burden quickly may result in permanent pulmonary hypertension or even death.”
